Antibody-incompatible kidney transplantation in 2015 and beyond

Nephrology Dialysis Transplantation

Volumn 30, Issue 12, 2015, Pages 1972-1978

  Higgins, Rob M ^a   Daga, Sunil ^b   Mitchell, Dan A ^b  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

ABO; Antibody; Antibody mediated rejection; HLA; Kidney transplant

Indexed keywords

ABO ANTIBODY; ANTIBODY; COMPLEMENT; HLA ANTIBODY; UNCLASSIFIED DRUG; BLOOD GROUP ABO SYSTEM; HLA ANTIGEN;

ALLOGRAFT; ANTIBODY DETECTION; ANTIBODY INCOMPATIBLE TRANSPLANTATION; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; BINDING AFFINITY; BINDING SITE; BLOOD GROUP ABO INCOMPATIBILITY; HUMAN; IMMUNE RESPONSE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; TIME FACTOR;

ABO BLOOD-GROUP SYSTEM; ANTIBODIES; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BLOOD GROUP INCOMPATIBILITY; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; TIME FACTORS;

EID: 84959422410     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu375     Document Type: Review

References (44)

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. New Engl J Med 1969; 280: 735-739
2. Higgins R, Lowe D, Hathaway M et al. HLA antibody incompatible renal transplantation: excellent medium term outcomes with negative cytotoxic crossmatch. Transplantation 2011; 92; 900-906
3. Gupta A, Iveson V, Varagunam M et al. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: Are they relevant? Transplantation 2008; 85: 1200-1204
4. Lefaucheur C, Loupy A, Hill GS et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406
5. Singh N, Djamali A, Lorentzen D et al. Pretransplant donor-specific antibodies detected by single-Antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 2010; 90: 1079-1084
6. Willicombe M, Brookes P, Santos-Nunez E et al. Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2011; 11: 470-477
7. Bentall A, Cornell LD, Gloor JM et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013; 13: 76-85
8. Loupy A, Lefaucheur C, Vernerey D et al. Complement-binding anti-HLA antibodies and kidney-Allograft survival. N Engl J Med 2013; 369: 1215-1226
9. Tait BD, Sösal C, Gebel HM et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47
10. Kahwaji J, Najjar R, Kancherla D et al. Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab. Clin Transpl 2014; 28: 546-553
11. Lefaucheur C, Loupy A, Vernerey D et al. Antibody-mediated vascular rejection of kidney allografts: A population-based study. Lancet 2013; 381: 313-319
12. Wiebe C, Gibson IW, Blydt-Hansen TD et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167
13. Tanabe K, Ishida H, Inui M et al. ABO-incompatible kidney transplantation: long-Term outcomes. Clin Transpl 2013: 307-312
14. Montgomery JR, Berger JC, Warren DS et al. Outcomes of ABO-incompatible kidney transplantation in the United States. Transplantation 2012; 93: 603-609
15. Haas M, Sis B, Racusen LC et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-Associated arterial lesions. Am J Transplant 2014; 14: 272-283
16. Taniguchi M, Rebellato LM, Cai J et al. Higher risk of kidney graft failure in the presence of anti-Angiotensin II type-1 receptor antibodies. Am J Transplant 2013; 13: 2577-2589
17. Dragun D, Catar R, Kusch A et al. Non-HLA-Antibodies targeting Angiotensin type 1 receptor and antibody mediated rejection. Hum Immunol 2012; 73: 1282-1286
18. Jackson AM, Kraus ES, Orandi BJ et al. A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int 2015; 87: 409-416
19. Higgins R, Lowe D, Hathaway M et al. Rises and falls in donor specific and third party HLA antibody levels after antibody incompatible transplantation. Transplantation 2009; 87: 882-888
20. Bentall A, Tyan DB, Sequeira F et al. Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int 2014; 27: 1235-1243
21. Everly MJ, Rebellato LM, Haisch CE et al. Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients. Transplantation 2014; 97: 494-501
22. Lowe D, Higgins R, Zehnder D et al. Significant IgG subclass heterogeneity in HLA-specific antibodies: implications for pathogenicity, prognosis, and the rejection response. Hum Immunol 2013; 74: 666-672
23. Naemi FM, Carter V, Kirby JA et al. Anti-donor HLA class I antibodies: pathways to endothelial cell activation and cell-mediated allograft rejection. Transplantation 2013; 96: 258-266
24. Ravindranath MH, Pham T, Ozawa M et al. Antibodies to HLA-E may account for the non-donor-specific anti-HLA class-Ia antibodies in renal and liver transplant recipients. Int Immunol 2012; 24: 43-57
25. Reed E, Hardy M, Benvenisty A et al. Effect of antiidiotypic antibodies to HLA on graft survival in renal-Allograft recipients. N Engl J Med 1987; 316: 1450-1455
26. Arnold ML, Heinemann FM, Horn P et al. 16(th) IHIW: Anti-HLA alloantibodies of the of IgA isotype in re-Transplant candidates. Int J Immunogenet 2013; 40: 17-20
27. El-Awar N, Terasaki PI, Cai J et al. Epitopes of HLA-A, B, C, DR, DQ, DP and MICA antigens. Clin Transpl 2009: 295-321
28. Hamer R, Molostvov G, Lowe D et al. Human leucocyte antigen-specific antibodies and gamma-interferon stimulate human microvascular and glomerular endothelial cells to produce complement factor C4. Transplantation 2012; 93; 867-873
29. Higgins R, Zehnder D, Chen K et al. The histological development of acute antibody-mediated rejection in HLA antibody incompatible renal transplantation. Nephrol Dial Transplant 2010; 25: 1306-1312
30. Halloran PF, Reeve JP, Pereira AB et al. Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies. Kidney Int 2014; 85: 258-264
31. Loupy A, Lefaucheur C, Vernerey D et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol 2014; 25: 2267-2277
32. Vo AA, Choi J, Cisneros K et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation 2014; 98: 312-319
33. Todeschini M, Cortinovis M, Perico N et al. In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-Thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. J Immunol 2013; 191: 2818-2828
34. Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256-3262
35. Banham G, Prezzi D, Harford S et al. Elevated pre-Transplant soluble BAFF is associated with an increased risk of acute antibody-mediated rejection. Transplantation 2013; 96: 413-420
36. Aubert O, Suberbielle C, Gauthe R et al. Effect of a proteasome inhibitor plus steroids on HLA antibodies in sensitized patients awaiting a renal transplant. Transplantation 2014; 97: 946-952
37. Walsh RC, Brailey P, Girnita A et al. Early and late acute antibodymediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011; 91: 1218-1226
38. Aklain E, Dinavahi R, Friedlander R et al. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitised patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008; 3: 1160-1167
39. Higgins RM, Lowe D, Hathaway M et al. Double filtration plasmapheresis in antibody incompatible kidney transplantation. Ther Apher Dial 2010; 14; 392-399
40. Morath C, Becker LE, Leo A et al. ABO-incompatible kidney transplantation enabled by non-Antigen-specific immunoadsorption. Transplantation 2012; 93: 827-834
41. McMurtrey C, Lowe D, Buchli R et al. Profiling antibodies to class II HLA in transplant patient sera. Hum Immunol 2014; 75: 261-270
42. Genberg H, Kumlien G, Wennberg L et al. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: A 3-year follow-up. Transplantation 2008; 85: 1745-1754
43. Stegall MD, Diwan T, Raghavaiah S et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-2413
44. Hamer R, Krishnan NS, Lowe D et al. C5b-9 inhibitor (eculizumab) for antibody-mediated rejection in renal transplantation. Indian J Transpl 2011; 5: 6-8